



COPY OF PAPERS
ORIGINALLY FILED

Doc # 00103.021US1
WD # 438291.wpd

UC Case No. 1999-238-2 (CIP)


Clean Version of Pending Claims

USE OF ETODOLAC IN THE TREATMENT OF CANCER

Applicant: Dennis A. Carson et al.

Serial No.: 09/589,476

B1 - Sub C1
1. A method to treat multiple myeloma comprising contacting mammalian cancer cells with an amount of a compound of formula (I):



wherein R¹ is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R², R³, R⁴ and R⁵ are the same or different and are each hydrogen or lower alkyl; R⁶ is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R⁷ is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C₁-C₃)alkyl(CO), wherein each alkyl is substituted with 0-2 (C₁-C₄) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino, or a pharmaceutically acceptable salt thereof, effective to reduce the viability of cancerous bone marrow cells.

B2
3. The method of claim 1 wherein the mammalian cancer cells are human cancer cells.

4. The method of claim 3, wherein the compound of formula (I) is administered to a human cancer patient.

B3
11. The method of claim 31, wherein the compound of formula (I) is R(-) etodolac.

B4
13. The method of claim 4, wherein the compound of formula (I) is administered orally.

BEST AVAILABLE COPY

By cont
14. The method of claim 31, wherein the 1-R(-) etodolac is administered orally.

B-5
26. A method of treating multiple myeloma comprising administering to a human patient afflicted therewith an amount of 1-R(-) etodolac effective to reduce the viability of multiple myeloma cells, while maintaining the viability of normal bone marrow cells.

27. The method of claim 26, wherein the 1-R(-) etodolac is administered orally.

sub
28. The method of claim 26 wherein a daily dosage of about 1000-5000 mg of R(-) etodolac is administered.

29. The method of claim 28 wherein the plasma concentration of etodolac is about 500-700 μ M.

B6
34. The method of claim 4, wherein the compound of formula (I) is etodolac.

35. The method of claim 1, wherein the compound of formula (I) is the 1-(R) enantiomer.

BEST AVAILABLE COPY